StreetInsider.com News Articles

Form 4 Stoke Therapeutics, Inc. For: Jul 16 Filed by: Harrison Seth Loring

Fri, 17 Jul 2026 16:37:00 -0400

si-local-file:///var/storage/secattach/20260717/26784785.html

Form 4 Stoke Therapeutics, Inc. For: Jul 16 Filed by: Harrison Seth Loring

Fri, 17 Jul 2026 16:37:00 -0400

si-local-file:///var/storage/secattach/20260717/26784785.html

Form 4 Stoke Therapeutics, Inc. For: Jul 15 Filed by: McCauley Thomas

Fri, 17 Jul 2026 16:36:00 -0400

si-local-file:///var/storage/secattach/20260717/26784773.html

Form 4 Stoke Therapeutics, Inc. For: Jul 15 Filed by: McCauley Thomas

Fri, 17 Jul 2026 16:36:00 -0400

si-local-file:///var/storage/secattach/20260717/26784773.html

Form 3 Stoke Therapeutics, Inc. For: Jul 13 Filed by: McCauley Thomas

Fri, 17 Jul 2026 16:33:00 -0400

si-local-file:///var/storage/secattach/20260717/26784756.html

Form 3 Stoke Therapeutics, Inc. For: Jul 13 Filed by: McCauley Thomas

Fri, 17 Jul 2026 16:33:00 -0400

si-local-file:///var/storage/secattach/20260717/26784756.html

Stoke Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

Thu, 16 Jul 2026 16:01:00 -0400

BEDFORD, Mass.--(BUSINESS WIRE)-- Stoke Therapeutics, Inc. (Nasdaq: STOK) is a biotechnology company dedicated to restoring protein expression by harnessing the body’s potential with RNA medicine and has a lead investigational medicine, zorevunersen, in development as a first-in-class potential disease-modifying treatment for Dravet syndrome. The Company today announced that, effective on July 15, 2026, it granted stock options to purchase shares of common stock to Thomas McCauley, the Company’s newly-appointed Chief Scientific Officer, and seven other new employees, as a material inducement to their employment in accordance with Nasdaq Listing Rule 5635(c)(4).

The company granted

Stoke Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

Thu, 16 Jul 2026 16:01:00 -0400

The company granted

Stoke Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

Thu, 16 Jul 2026 16:01:00 -0400

The company granted

Stoke Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

Thu, 16 Jul 2026 16:01:00 -0400

The company granted

Stoke Therapeutics names Thomas McCauley as chief scientific officer

Mon, 13 Jul 2026 07:30:51 -0400

Stoke Therapeutics, Inc. (Nasdaq: STOK) has appointed Thomas McCauley, Ph.D., as chief scientific officer, the Bedford, Massachusetts-based biotechnology company announced.

Dr. McCauley joins Stoke with more than 25 years of experience leading research and development teams. He most recently served as president and chief executive officer of Neptune Bio. He has also held the role of chief scientific officer at Omega Therapeutics, Macrolide Pharmaceuticals, and Translate Bio. Earlier in his career, he held leadership roles at Shire, where he was involved in the late-stage development and global approvals of multiple genetic medicines for rare diseases, as well as at Inotek Pharmaceuticals

Stoke Therapeutics names Thomas McCauley as chief scientific officer

Mon, 13 Jul 2026 07:30:51 -0400

Stoke Therapeutics, Inc. (Nasdaq: STOK) has appointed Thomas McCauley, Ph.D., as chief scientific officer, the Bedford, Massachusetts-based biotechnology company announced.

Stoke Therapeutics names Thomas McCauley as chief scientific officer

Mon, 13 Jul 2026 07:30:51 -0400

Stoke Therapeutics, Inc. (Nasdaq: STOK) has appointed Thomas McCauley, Ph.D., as chief scientific officer, the Bedford, Massachusetts-based biotechnology company announced.

Stoke Therapeutics names Thomas McCauley as chief scientific officer

Mon, 13 Jul 2026 07:30:51 -0400

Stoke Therapeutics, Inc. (Nasdaq: STOK) has appointed Thomas McCauley, Ph.D., as chief scientific officer, the Bedford, Massachusetts-based biotechnology company announced.

Stoke Therapeutics Appoints Thomas McCauley, Ph.D., as Chief Scientific Officer

Mon, 13 Jul 2026 07:30:00 -0400

–Dr. McCauley brings more than 25 years of experience building high-performing R&D organizations and translating early scientific discoveries into new medicines for people with severe diseases–